Product Overview
Dragon Pharma Arimidex is anastrozole in 1 mg tablets, a non-steroidal and reversible aromatase inhibitor of the type II class. It is an ancillary product, not a performance compound: nothing about it adds muscle, and it is taken only when the cycle it supports produces more estrogen than the body handles well. Tablets are produced under GMP conditions with the active mass stated on the pack, and the 1 mg unit is the strength used in the dosing ranges below.
The mechanism is specific. Anastrozole binds the haem portion of the aromatase cytochrome P450 enzyme and blocks the conversion of androgens into estrogens, which lowers circulating estradiol rather than blocking the receptor. That is the line between this product and a SERM such as Nolvadex, which works at the receptor and does not stop production of estradiol at all. The elimination half-life is 40 to 50 hours, close to the roughly 50 hour terminal figure in the label for postmenopausal women, so a steady level is held with once daily or every other day dosing. At 1 mg per day estradiol falls by at least 85 percent in the postmenopausal data, which is why the dose is not a matter of taste.
The material belongs to cycles built on aromatising compounds. A testosterone base such as Cypionat 250 or Enantat 250, or a blend like Sustanon 270, is the usual context, and an oral such as Dianabol 20 adds to the same load. Within that setting the inhibitor controls water retention, breast sensitivity and blood pressure driven by estrogen. It does not remove the cause of aromatisation; it manages the consequence, which is the honest way to read its role.
Dosage Protocol
Anastrozole is dosed against a measured estradiol level, and the tablet strength allows the small steps that approach requires. The table follows the reference ranges in the sources for this card.
| Beginner | 0.5 mg every other day as a low starting step, set by estradiol results |
| Intermediate | 1 mg every other day with estradiol checked rather than guessed |
| Advanced | 1 mg per day or more only when high estrogen is confirmed by blood work |
| Female | Not used in this context; the drug controls estrogen in men on an aromatising cycle |
| Administration | Oral, once daily or every other day; the 40-50 hour half-life holds a level between doses |
| Duration | Runs with the length of the underlying cycle, not as a fixed course with its own endpoint |
Suggested Protocols
The inhibitor is chosen for a stack, never on its own. Three settings cover how it is actually used, and in each one the dose follows the blood results rather than the plan on paper.
What to Expect
- Estradiol falls. The drop appears within 1-2 weeks of starting, which is why the first blood check sits in that window.
- Less estrogen-driven water. Puffiness and breast sensitivity linked to high estrogen ease off when the level is brought into range.
- Steady levels. With a half-life of 40-50 hours, once daily or every other day dosing holds the effect without peaks between doses.
- Over-suppression. Too much produces dry, aching joints, a drop in libido and worse lipids, the opposite of what the product is taken for.
- Cause versus consequence. The tablet manages the fallout of aromatisation and does not reduce the amount of aromatising compound in the cycle.
- Long-term use in men. Prolonged dosing can affect bone density, so it is not a product to keep running out of habit.
- Limitation. The lowest dose that holds estradiol in range is the target; more is not better and is the most common mistake with this class.
Side Effects and Management
Almost every complaint here is a sign of too little estrogen rather than of the drug itself, and the answer is a step down in dose confirmed by a blood test.
Cycle Support and Follow-Up
Anastrozole is not a recovery drug and the sources list no post-cycle step for it. It does not suppress the hypothalamic-pituitary-gonadal axis, so a SERM after a cycle such as Nolvadex or Clomid is aimed at the underlying cycle, not at the inhibitor. What belongs here is a monitoring plan.
